Advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression.
VIEW PRODUCT PIPELINEAbout
We are a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders.
Read MoreNews
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
March 12, 2024
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
March 5, 2024
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 29, 2024
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
February 22, 2024
Product Pipeline
XEN1101
for Focal Onset Seizures (FOS)
X-TOLE2/3 Clinical Trial
XEN1101
for Primary Generalized Tonic-Clonic Seizures (PGTCS)
X-ACKT Clinical Trial
XEN1101
for Major Depressive Disorder (MDD)
X-NOVA Clinical trial
XEN1101
for MDD
Investigator-led Phase 2 POC study Collaboration with Mount Sinai
NBI-921352
for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area